contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Yeah, that’s how it went with Traumakine. I recall Markku Jalkanen mentioning in a media interview back then that they already had champagne ready in the company fridge, but it remained unopened for the time being. Well, Bex is a different story. Since we’re invested in this, we have to have enough optimism to believe that after all the financial and communication fiascos, it will eventually make it to the market. Although, of course, there’s nowhere near 100% certainty.

Didn’t the same thing happen to Faron with Traumakine, the F3 failure came out of nowhere?

In London, different over the last few days than on the Helsinki Stock Exchange

Over the weekend, the forum saw a cautionary tale in another junior development company about what can happen to investors in these firms. Extremely promising Phase II results and a huge need for the product, so just finish the last phase and money will flow in. After a long wait, a bomb drops from the final tests. It doesn’t work and development should no longer continue:   And the course reaction was accordingly:   These small drug development companies are harsh targets for investors, as the final truth about functionality is revealed only later, and no matter how good it looks and how much effort is put into scraping together funding, the rug can always be pulled from under the company’s feet. Of course, one hopes for similar return potential for such a huge risk, but one should not stuff too large a portion of their portfolio into long shots like Faron.

I wonder why the trading of warrants has needed to be (and could be) suspended on AIM, when they weren’t supposed to be traded today anyway?

AIM 30 March 2026 NOTICE 30/03/2026 7:30am TEMPORARY SUSPENSION OF TRADING ON AIM FARON PHARMACEUTICALS OY At the request of the Company, trading on AIM for the under-mentioned securities was temporarily suspended from 30/03/2026 7:30am, pending an announcement. SUBSCRIPTION RIGHTS, NIL PAID (DI) (BS84X55) (FI4000602313) If you have any queries relating to the above, please contact the Company’s nominated adviser on [+44 (0) 207 213 0880](tel:+44 0 207 213 0880). Seems unusual this is just AIM and the “suspension pending an announcement of the subscription rights”.

Work is apparently being done diligently at Faron and in the chain. Faron had previously filed a patent application for the use of soluble Clever or part thereof for the management of autoimmune diseases or other inflammatory conditions US20220227858A1 - Controlling of immune activation by soluble clever-1 - Google Patents, where it states “abandoned”. It spoke of the binding site RACK, which in subsequent studies changed to IGF2R. Now, a WIPO patent (i.e., a worldwide patent) is being sought. First, it will be investigated whether a similar invention has been made, and if not, Faron can use the statement for actual patent applications in different countries without having to start from scratch in each country; the invention is now protected. Now, a more precisely defined part of the Clever-1 molecule is being sought, the production of which is also described https://patentscope.wipo.int/search/en/WO2026057922. Thus, it is not worthwhile to produce a whole large Clever, as its smaller T-cell-affecting part has been identified. Recombination is produced in cell culture (e.g., in this case, with Chinese hamster cells). The mechanism is precisely shown: it binds to the IGF2R receptor on T-cells via mannose-6-phosphate → disrupts the TCR signal → weakens the Th1 response, promotes FoxP3+ suppressive CD8+ T-cells. The application remains the management of inflammatory conditions, including autoimmune diseases. This is one step towards drug development. The effect is thus the opposite of Bex. Clinical application is still a long way off, but the value of the Clever-1/Bex patent family is constantly increasing.

Faron Pharmaceuticals

Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk ...

<p>Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk investment as drug development requires frontloaded investments in research, while the success of commercialization is very uncertain. If the drug candidates enter the market, the invested capital can be multiplied. However, failure of drug development is frequent and, in that case, the invested capital may be partially or totally lost. We believe the share provides sufficient expected return to counterbalance the high risk. The share is suitable for a long-term investor that tolerates high risk as part of a well-diversified portfolio. A person investing in Faron must also be prepared for share issues.</p> 

	2021	22e	23e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-21.1	-22.0	-0.8
EBIT-% (adj.)	-527,700.0 %	-550,000.0 %	-19,500.0 %
EPS (adj.)	-0.38	-0.39	-0.02
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Risky investment with huge potential

Key Estimate Figures2022-08-08

Forum discussions